Personalized Use of Resources Study (PURE)
The PURE study is investigating how to best use medicines for people who have had a kidney transplant. Specifically, it's comparing different forms of a drug called tacrolimus, which helps prevent the new kidney from being rejected. Researchers want to see if a prolonged-release version (Envarsus) can be given at a lower dose than another prolonged-release version (Advagraf) while still maintaining the correct level of medicine in the body. The goal is to make treatment easier for patients by potentially reducing the number of pills they need to take, reducing side effects, and making sure the medicine works more consistently. This study focuses on individuals where the medicine might not be absorbed as expected, to find the most effective and patient-friendly way to manage their anti-rejection medication.
At a glance
What is this study about?
The PURE study aims to improve how we use an important medicine called tacrolimus in people who have had a kidney transplant. Tacrolimus is crucial because it helps to stop your body from rejecting the new kidney. There are different forms of this medicine, including two types that release the drug slowly over time. This study wants to find out if one of these newer, slow-release forms (called Envarsus) can be given at a lower dose than another slow-release form (called Advagraf) while still keeping the right amount of medicine in your body.
Finding the right dose is really important. If the dose is too high, it can cause unwanted side effects. If it's too low, it might not protect your new kidney properly. By potentially using a lower dose, researchers hope to reduce the amount of medicine you need to take and make it work more smoothly throughout the day. This could lead to fewer side effects and make your daily medication routine simpler.
This study is particularly looking at people whose bodies might not process tacrolimus in the usual way. The aim is to find a more personalised approach to treatment, ensuring that patients receive the most effective dose with the fewest possible problems. Ultimately, the PURE study is about making life better for people with kidney transplants by making their anti-rejection medication regime as effective and comfortable as possible.
Key takeaways
- The PURE study aims to find the best way to use tacrolimus for kidney transplant patients.
- It compares two slow-release forms of tacrolimus, Advagraf and Envarsus.
- The goal is to reduce pill burden and side effects while maintaining effective drug levels.
- The study focuses on personalising medicine doses for better patient outcomes.
- Both male and female adults can potentially participate.
Who may be eligible?
To be considered for the PURE study, you would need to be an adult, meaning you are 18 years old or older. There is no upper age limit for taking part.
Both men and women are welcome to participate in this study. The researchers are looking for a wide range of people to ensure the findings apply to many different patients.
Specific medical details, such as how your body is currently reacting to your anti-rejection medication, will also be important. The study is particularly interested in people whose current level of tacrolimus in their body isn't quite as expected compared to the dose they are taking.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you had a kidney transplant?
- Are you currently taking tacrolimus medication?
- Has your doctor mentioned that your tacrolimus levels are not quite as expected for your dose?
What does participation involve?
If you decide to join the PURE study, you would be taking one of the slow-release tacrolimus medications (either Advagraf or Envarsus). You would have regular appointments where blood tests would be taken to check the level of the medicine in your body. This helps doctors make sure you're on the right dose. They would be comparing how well the different medicines work, how many pills you need to take, and if you experience any side effects. The study aims to understand the best way to use these important anti-rejection medicines. The total duration of your participation would depend on the study's design, but it typically involves a period of taking the medicine under close medical supervision and regular check-ups.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is tacrolimus?
Tacrolimus is a medicine given to people who have had a kidney transplant. It helps stop your body from rejecting the new kidney.
Why are there different versions of tacrolimus?
Different versions, like Advagraf and Envarsus, are designed to release the medicine in different ways. This study wants to see which one works best and is easiest for patients.
What does 'lower dose' mean for me?
A lower dose, if it's still effective, could mean you take fewer pills, which might lead to fewer side effects and make it easier to stick to your treatment plan.
Is this study safe?
Yes, all clinical studies go through strict checks to ensure patient safety. Your health will be carefully monitored throughout the study by medical professionals.
Will my regular doctor still look after me?
Yes, your usual medical care will continue. The study team will work with your doctor to make sure your treatment is well coordinated.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.